Overview

Study to Evaluate the Safety and Efficacy of Phenoptin™ in Subjects With Phenylketonuria Who Have Elevated Phenylalanine Levels

Status:
Completed

Trial end date:
2006-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of Phenoptin™ (sapropterin dihydrochloride) in reducing blood phenylalanine (Phe) levels in subjects with phenylketonuria.

Phase:

Phase 3

Details

Lead Sponsor:

BioMarin Pharmaceutical

Treatments:

Verapamil